The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan-Kettering Cancer Center. Published in the New England Journal of Medicine, the study offers new hope for patients with a disease that can have a poor prognosis. Read more here.
Study mentioned: Ho AL, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013 Feb 14;368(7):623-32. PMID: 23406027
No comments:
Post a Comment